Capital International Investors Bei Gene, Ltd. Transaction History

Capital International Investors

$557 Billion
Q2 2025

A detailed history of Capital International Investors transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International Investors holds 4,885,006 shares of BGNE stock, worth $1.11 Billion. This represents 0.2% of its overall portfolio holdings.

Number of Shares

4,885,006

Previous 5,090,970 4.05%

Holding current value

$1.11 Billion

Previous $1.15 Billion 4.05%

% of portfolio

0.2%

Previous 0.24%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	N/A	-205,964 Reduced 4.05%	4,885,006 $1.11 Billion
Q1 2025 May 12, 2025	SELL	$175.1 - $226.71 $179 Million - $232 Million	-1,022,195 Reduced 16.72%	5,090,970 $1.15 Billion
Q4 2024 Feb 13, 2025	SELL	$174.72 - $246.04 $55.5 Million - $78.2 Million	-317,719 Reduced 4.94%	6,113,165 $1.13 Billion
Q3 2024 Nov 13, 2024	SELL	$143.93 - $224.51 $83.9 Million - $131 Million	-582,684 Reduced 8.31%	6,430,884 $1.44 Billion
Q2 2024 Aug 13, 2024	SELL	$129.52 - $174.32 $6.59 Million - $8.87 Million	-50,860 Reduced 0.72%	7,013,568 $1 Billion
Q1 2024 May 14, 2024	BUY	$141.8 - $181.47 $103 Million - $132 Million	727,556 Added 11.48%	7,064,428 $1.1 Billion
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $45.3 Million - $57.5 Million	285,397 Added 4.72%	6,336,872 $1.14 Billion
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $43.9 Million - $54.9 Million	-243,924 Reduced 3.87%	6,051,475 $1.09 Billion
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $48.2 Million - $72.1 Million	-270,200 Reduced 4.12%	6,295,399 $1.12 Billion
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $45.7 Million - $58.2 Million	-211,846 Reduced 3.13%	6,565,599 $1.42 Billion
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $23.4 Million - $42.7 Million	186,203 Added 2.83%	6,777,445 $1.49 Billion
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $28.1 Million - $43.1 Million	-213,048 Reduced 3.13%	6,591,242 $889 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $30.4 Million - $54.2 Million	-251,005 Reduced 3.56%	6,804,290 $1.1 Billion
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $104 Million - $192 Million	711,396 Added 11.21%	7,055,295 $1.34 Billion
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $4.97 Million - $7.78 Million	19,980 Added 0.32%	6,343,899 $1.72 Billion
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $95.9 Million - $155 Million	384,269 Added 6.47%	6,323,919 $2.3 Billion
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $41.7 Million - $52.3 Million	142,499 Added 2.46%	5,939,650 $2.04 Billion
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $112 Million - $164 Million	428,521 Added 7.98%	5,797,151 $2.01 Billion
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $131 Million - $188 Million	-593,750 Reduced 9.96%	5,368,630 $1.39 Billion
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $1.69 Million - $2.56 Million	8,945 Added 0.15%	5,962,380 $1.71 Billion
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $30.6 Million - $48.2 Million	246,826 Added 4.33%	5,953,435 $1.12 Billion
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $141 Million - $200 Million	1,155,679 Added 25.39%	5,706,609 $703 Million
Q4 2019 Feb 18, 2020	BUY	$115.78 - $208.34 $116 Million - $208 Million	998,037 Added 28.09%	4,550,930 $754 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $131 Million - $161 Million	1,082,594 Added 43.82%	3,552,893 $435 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $71.4 Million - $92 Million	626,368 Added 33.97%	2,470,299 $306 Million
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $101 Million - $124 Million	818,425 Added 79.81%	1,843,931 $593 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $110 Million - $180 Million	1,025,506 New	1,025,506 $144 Million

Others Institutions Holding BGNE

# of Institutions

269

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account

Capital International Investors Bei Gene, Ltd. Transaction History